XERS
Xeris Biopharma Holdings, Inc.Company with tickers: XERS
CIK
1867096
CUSIP
98422E103
Shares Outstanding
172,642,055
13F Activity (30d)
195 filings
190 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $83,127,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $8,783,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $7,916,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $2,234,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $0.01 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $0.01 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |